Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kapil Gudala

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Pain Physician|January 11, 2017
Vitamin D Supplementation in Patients with Chronic Low Back Pain: An Open Label, Single Arm Clinical TrialBabita Ghai, Dipika Bansal, Raju Kanukula, et al.
Pharmacoeconomics|April 1, 2021
Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in SwitzerlandNadine Schur, Kapil Gudala, Umakanth Vudumula, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|April 4, 2022
Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in GermanyDominik Koeditz, Juergen Frensch, Martin Bierbaum, et al.
Journal of Comparative Effectiveness Research|August 22, 2023
Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in CanadaVirender Bhan, Fraser Clift, Moogeh Baharnoori, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Pain Physician|January 11, 2017
Vitamin D Supplementation in Patients with Chronic Low Back Pain: An Open Label, Single Arm Clinical TrialBabita Ghai, Dipika Bansal, Raju Kanukula, et al.
Pharmacoeconomics|April 1, 2021
Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Disease in SwitzerlandNadine Schur, Kapil Gudala, Umakanth Vudumula, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|April 4, 2022
Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence analysis from a societal perspective in GermanyDominik Koeditz, Juergen Frensch, Martin Bierbaum, et al.
Journal of Comparative Effectiveness Research|August 22, 2023
Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in CanadaVirender Bhan, Fraser Clift, Moogeh Baharnoori, et al.
Pageof 3